PBAC's latest decision on Thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter 2 inhibitors: Deferred (2014). Considered for Third-line treatment of type 2 diabetes mellitus after failure of first and second-line treatment options.
PBAC outcome
Deferred
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Adult patients with type 2 diabetes mellitus who have failed at least two second-line dual therapy combinations, including either metformin plus sulfonylurea AND metformin plus gliptin, or gliptin with sulfonylurea.
Therapy area
Diabetes
Line of therapy
Later-line
Evidence base
Other
Economic model
Not modelled
ICER note
This is not a new submission for a single drug; it concerns proposed changes to PBS restrictions for existing third-line diabetes agents. No ICER is provided or calculated.
Risk sharing
Risk-sharing arrangement in place — The PBAC recommended that gliflozins which remain subsidised only in the third-line setting have their risk sharing arrangements (RSA) reviewed due to expected reduction in eligible patient numbers following the shift of gliptins to second-line subsidy.